ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
6.44
+0.09 (1.42%)
At close: Apr 2, 2026, 4:00 PM EDT
6.57
+0.13 (2.02%)
After-hours: Apr 2, 2026, 4:45 PM EDT
ImmuCell Employees
As of September 30, 2025, ImmuCell had 84 total employees, including 77 full-time and 7 part-time employees. The number of employees increased by 5 or 6.33% compared to the same quarter last year.
Employees
84
Change
5
Growth
6.33%
Revenue / Employee
$329,097
Profits / Employee
-$12,381
Market Cap
58.26M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 142 |
| MindWalk Holdings | 102 |
| Acrivon Therapeutics | 76 |
| Kezar Life Sciences | 55 |
| OnKure Therapeutics | 45 |
| Entera Bio | 22 |
| ImageneBio | 15 |
| Instil Bio | 14 |
ICCC News
- 17 days ago - ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board - GlobeNewsWire
- 4 weeks ago - ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025 - GlobeNewsWire
- 6 weeks ago - ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025 - GlobeNewsWire
- 3 months ago - ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript - Seeking Alpha
- 3 months ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 - GlobeNewsWire
- 3 months ago - ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus - GlobeNewsWire
- 3 months ago - ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain® - GlobeNewsWire